BGLC (BioNexus Gene Lab) 12-1 Month Momentum % : -52.29% (As of Dec. 16, 2024)

View and export this data going back to 2020. Start your Free Trial

What is BioNexus Gene Lab 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-12-16), BioNexus Gene Lab's 12-1 Month Momentum % is -52.29%.

The industry rank for BioNexus Gene Lab's 12-1 Month Momentum % or its related term are showing as below:

BGLC's 12-1 Month Momentum % is ranked worse than
96.53% of 1556 companies
in the Chemicals industry
Industry Median: -2.42 vs BGLC: -52.29

Competitive Comparison of BioNexus Gene Lab's 12-1 Month Momentum %

For the Specialty Chemicals subindustry, BioNexus Gene Lab's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNexus Gene Lab's 12-1 Month Momentum % Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where BioNexus Gene Lab's 12-1 Month Momentum % falls into.

BioNexus Gene Lab (NAS:BGLC) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNexus Gene Lab (NAS:BGLC) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

BioNexus Gene Lab 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of BioNexus Gene Lab's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNexus Gene Lab Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioNexus Gene Lab Corp (NAS:BGLC) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 8 Jalan Kerinchi, The Vertical Business Suite II, Unit 02, Level 10, Tower B, Avenue 3, Bangar South, Kuala Lumpur, SGR, MYS, 59200

Website

https://www.bionexusgenelab.com

BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.

Executives

Chak Hua Yew	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yeat Min Fong	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Teng Fook Fong	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chee Keong Yap	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Boon Teong Teoh	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Yee Meng Wong	director, officer: President	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Wei Li Leong	officer: Chief Financial Officer	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chai Ping Lin	director	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Tai Tan Liong	director, officer: Chief Operating Officer	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Sook Keng Yeoh	director, officer: Chief Executive Officer	10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200